Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV- infected patients on highly active antiretroviral therapy (HAART)

Diabetes and Metabolism

Volumn 25, Issue 3, 1999, Pages 225-232

  Vigouroux, C ^b   Gharakhanian, S ^b   Salhi, Y ^b   Nguyen, T H ^b   Chevenne, D ^c   Capeau, J ^a,b   Rozenbaum, W ^b  

^a INSERM   (France)

^b HÔPITAL ROTHSCHILD   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Diabetes; Hypertriglyceridaemia; Insulin resistance; Lipodystrophy; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; GLUCOSE TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; MALE; ORAL GLUCOSE TOLERANCE TEST;

EID: 0032836828     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med, 1997, 337, 725-733.
2. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet, 1997, 350, 1596.
3. Lo JC, Mulligan K, Tai VW, Heather A, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet, 1998, 351, 867-870.
4. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral-fat accumulation associated with use of indinavir. Lancet, 1998, 351, 871-875.
5. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS, 1998, 12, F37-F39.
6. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 1998, 12, F51-F58.
7. Walli R, Herfort O, Michl GM et al. Treatment with protease inhibitors associated with peripheral insulin resitance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS, 1998, 12, F167-173.
8. Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycemia. Lancet, 1997, 350, 713-714.
9. Vigouroux C, Khallouf E, Bourut C et al. Genetic exclusion of fourteen candidate genes in lipoatrophic diabetes using linkage analysis in ten consanguineous families. J Clin Endocrinol Metab, 1997, 82, 3438-3444.
10. Robert J-J, Rakotoambinina B, Cochet I et al. The development of hyperglycemia in patients with insulin-resistant generalized lipoatrophic syndromes. Diabetologia, 1993, 36, 1288-1292.
11. Léger J, Lévy-Marchal C, Bloch J et al. Reduced final height and indications for early development of insulin resistance in a 20 year old population born with intra-uterine growth retardation. BMJ, 1997, 315, 341-347.
12. Siegel S. Non-parametric statistics for the behavioral sciences. New York: McGraw Hill, 1956, 202.
13. Alberti KGMM, Zimmet PZ, for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Med, 1998, 15, 539-553.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985, 28, 412-419.
15. Chevenne D, Léger J, Lévy-Marchal C et al. Proinsulin and specific insulin responses to an oral glucose tolerance test in a healthy population. Diabetes Metab, 1998, 24, 260-261.
16. Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes, 1997 46, 1725-1732.
17. Henry K, Melroe H, Huebsch J et al. Severe premature coronary artery disease with protease inhibitors. Lancet, 1998, 351, 1328.
18. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med, 1997, 127, 947.
19. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose-fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet, 1963, i, 785-789.
20. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet, 1998, 351, 1881-1883.